2型糖尿病随机二线治疗对包含血糖控制、体重与低血糖的复合结局的比较效果:GRADE研究分析
在GRADE研究(5047例,平均随访5.0年)中,比较四种加用二甲双胍的随机治疗对复合结局(HbA1c>7.5%确认、体重增加≥5%、严重或反复非严重低血糖)的影响。复合结局风险利拉鲁肽组最低(19/100治疗人年),格列美脲组最高(40/100治疗人年),所有两两比较均有统计学意义。达到复合结局者治疗满意度略低但显著。
要点
- 复合结局风险由低到高:利拉鲁肽19、西格列汀26、甘精胰岛素29、格列美脲40(每100治疗人年),两两比较均显著。
- 体重增加和低血糖风险排序与复合结局相同,但血糖恶化风险以甘精胰岛素最低。
- 预设协变量间复合结局风险未见显著异质性,达到复合结局者治疗满意度略低但显著。
核心结论
- 在2型糖尿病常用二线药物类别治疗中,利拉鲁肽组复合结局风险最低,格列美脲组最高,该复合结局涵盖血糖恶化、体重增加和低血糖。
- 这些发现可能为2型糖尿病治疗决策提供信息。
研究设计与样本
- GRADE研究为随机比较效果研究,共5047例参与者,平均随访5.0年,比较四种加用二甲双胍的降糖治疗。
- 复合结局定义为以下任一事件首次发生的时间:确认HbA1c>7.5%、体重增加≥5%、严重或反复非严重低血糖。
- 采用Kaplan-Meier法估计累积发生率,Cox比例风险模型评估组间风险差异。
主要发现
- 复合结局风险(每100治疗人年事件数):利拉鲁肽19,西格列汀26,甘精胰岛素29,格列美脲40;所有两两比较均有统计学意义。
- 体重增加和低血糖风险排序与复合结局相同;血糖恶化风险以甘精胰岛素最低,其次为利拉鲁肽、格列美脲、西格列汀。
- 预设协变量间未检测到复合结局风险的显著异质性。
- 达到复合结局的参与者治疗满意度略低但显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (5,047 participants, mean follow-up 5.0 years), differences in glycemic control were demonstrated over time among four randomized therapies added to metformin. Weight gain and hypoglycemia are also important outcomes for people with type 2 diabetes. We compared the effects of the four randomized GRADE medications on a composite outcome incorporating glycemic deterioration, weight gain, and hypoglycemia. RESEARCH DESIGN AND METHODS: The composite outcome was time to first occurrence of any of the following: HbA1c >7.5%, confirmed; ≥5% weight gain; or severe or recurrent nonsevere hypoglycemia. Secondary analyses included examination of individual components of the composite outcome, subgroup effects and potential mediators, and treatment satisfaction. Cumulative incidence was estimated with the Kaplan-Meier estimator. Cox proportional hazards models were used to assess pairwise group differences in risk of an outcome. RESULTS: Risk of reaching the composite outcome (events per 100 participants per treatment year [PTYs]) was lowest with liraglutide (19 per 100 PTYs) followed by sitagliptin (26 per 100 PTYs), glargine (29 per 100 PTYs), and glimepiride (40 per 100 PTYs); all pairwise comparisons were statistically significant. The order was the same for risk of weight gain and hypoglycemia, but risk of glycemic deterioration was lowest with glargine, followed by liraglutide, glimepiride, and sitagliptin. No significant heterogeneity in risk of composite outcome was detected across prespecified covariates. Participants who reached the composite outcome had modestly but significantly lower treatment satisfaction. CONCLUSIONS: Among participants treated with common second-line drug classes for type 2 diabetes, the liraglutide group had the lowest and glimepiride the highest risk of reaching a composite outcome encompassing glycemic deterioration, weight gain, and hypoglycemia. These findings may inform decision-making regarding type 2 diabetes therapy.
引用
- Kirkman MS, Tripputi M, Krause-Steinrauf H, et al. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. PMID: 38194519. doi:10.2337/dc23-1332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。